RxDoctor Payments Data

Olga Maric, MD

Internal Medicine · Crystal River, FLNPI 1972581361

Payments from drug & device makers

$624in general payments, 2019–2025

Across 19 payments — averaging $32.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$166
  • Novo Nordisk$122
  • Lilly USA, LLC$92
  • Cardiovascular Systems Inc.$68
  • GSK$41
  • Gilead$41
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$56490%
  • Education$6010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$8,425
Medicare patients
29
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$82,390
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$72,602
JardianceEmpagliflozin35$46,637
EntrestoSacubitril/Valsartan30$42,448
JanuviaSitagliptin Phosphate18$25,175
EliquisApixaban29$24,569
XareltoRivaroxaban15$21,462
MounjaroTirzepatide18$18,707
MyrbetriqMirabegron13$15,954
Tresiba Flextouch U-100Insulin Degludec18$12,338
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,140
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$8,956
Duloxetine Hcl121$6,352
SymbicortBudesonide/Formoterol Fumarate14$5,465
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$122$82,39071 claims
GSKTrelegy Ellipta, Anoro Ellipta$41$81,74280 claims
PfizerEliquis, Paxlovid$19$25,96142 claims
Lilly USA, LLCMounjaro$92$18,70718 claims
Astellas Pharma US IncMyrbetriq$166$15,95413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Crystal River

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →